Brief: Puma Biotechnology Announces Exclusive License Agreement With Takeda For Development, Commercialization Of Alisertib

Puma Biotechnology

20/09/2022 21:11

Sept 20 (Reuters) - Puma Biotechnology Inc  PBYI.O :
    * PUMA BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT
WITH
TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALISERTIB,
AN INVESTIGATIONAL AURORA KINASE A INHIBITOR
    * PUMA BIOTECHNOLOGY INC - UNDER TERMS OF AGREEMENT, PUMA
WILL
ASSUME SOLE RESPONSIBILITY FOR GLOBAL DEVELOPMENT AND
COMMERCIALIZATION OF ALISERTIB
    * PUMA BIOTECHNOLOGY INC - TAKEDA WILL RECEIVE AN UPFRONT
LICENSE
FEE OF $7 MILLION FROM DEAL
    * PUMA BIOTECHNOLOGY INC -  TAKEDA IS ELIGIBLE TO RECEIVE
TIERED
ROYALTY PAYMENTS FOR ANY NET SALES OF ALISERTIB

Source text for Eikon:  ID:nBw9hPnmNa 
Further company coverage:  PBYI.O